Imlygic, also known as talimogene laherparepvec (T-Vec), is recommended to treat adults with unresectable melanoma that is regionally or distantly metastatic with no bone, brain, lung or other
Turing acquired the US rights to Daraprim in August this year and was criticized severely for increasing the price of the drug to $750 per tablet from $13.50
Merck owns both Physicians Interactive and Univadis. Financial terms of transaction were not disclosed. Univadis’s membership includes over 3 million healthcare providers in more than 90 countries. It
The expanded deal will see both the companies evaluate the safety and efficacy of a range of additional combinations across their portfolios. Lilly will lead the studies, while
The Add-Aspirin phase III trial is funded by Cancer Research UK and the National Institute for Health Research. It aims is to establish whether taking aspirin every day
Onivyde, in combination with chemotherapy drugs fluorouracil (5-FU) and leucovorin has been approved for treatment of metastatic pancreatic cancer patients who have undergone gemcitabine-based chemotherapy. The drug’s effectiveness
The Swiss pharma firm has also signed licensing agreements with drug developers Palobiofarma and XOMA. The transactions add Admune’s IL-15 agonist program, Palobiofarma’s PBF-509 adenosine receptor and Xoma’s
RXI-231 is an sd-rxRNA compound developed to target Tyrosinase (TYR), which is an important enzyme in the synthesis of melanin, the pigment that gives human skin, hair and
Clarient, which employees about 415 people, booked $127m in revenues and $13M in EBITDA in 2014. Clarient Diagnostic Services offers a range of cancer diagnostic testing services to
The company will use technology developed by QIMR Berghofer. It complements Atara’s ongoing CTL development by selectively targeting certain epitopes and antigens. The first applications where the technology
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.